The first eight fusions, which had ARHGAP26, RHOA, SLC1A2, UBR4, PGAP3, UBE2L3, PREX1 and PPAPDC1A as fusion partners, were previously reported with different fusion partners by the gastric cancer TCGA project (CLDN18-ARHGAP26, PRKAR2A-RHOA, CD44-SLC1A2, PIK3CD-UBR4, STARD3-PGAP3, and HNF1B-PGAP3) or in the literature7,17–21. Here, CD44 is linked to gastric cancer.